Vertex Pharmaceuticals
BiotechVertex Pharmaceuticals is a biotechnology company focused on Respiratory, Infectious Disease, Immunology. Key products include Casgevy.
FDA Novel Drug Designations
(2018-2025)See 4 novel approvals →
Vertex Pharmaceuticals at a Glance
- Leading 39 drug targets across portfolio
- Fast trial execution (12 months median completion)
Upcoming FDA Decisions
Full Calendar →Vertex Pharmaceuticals's Key Drugs
Vertex Pharmaceuticals's core commercial portfolio centers on ALYFTREK, KALYDECO, ORKAMBI, spanning Respiratory and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Vertex Pharmaceuticals News
All Vertex Pharmaceuticals news →- Nov 2, 2026 EarningsVertex Reports Third Quarter 2026 Financial Results ↗
- Oct 23, 2026 TrialsPhase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 ↗
- Oct 9, 2026 TrialsVertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference ↗
- Sep 22, 2026 TrialsVertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial ↗
- Sep 1, 2026 DealsVertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team ↗
Vertex Pharmaceuticals's Recent FDA Approvals
Vertex Pharmaceuticals secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Vertex Pharmaceuticals's Therapeutic Areas
Vertex Pharmaceuticals's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Infectious Disease, across 1 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Vertex Pharmaceuticals's Top Competitors
Vertex Pharmaceuticals's closest competitors by therapeutic-area and drug-target overlap include GSK, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Vertex Pharmaceuticals Pipeline Snapshot
Vertex Pharmaceuticals has 140 active clinical programs from ClinicalTrials.gov — 68 Phase 3, 34 Phase 2 and 38 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 59/79 completed
- • Speed: 12 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 2011-05-23
- Latest
- 2026-03-27
- Applications
- 11
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges